Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 3/20 | 0.45 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.45 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17934358 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL75258 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL9887148 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL1787909 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL29936790 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL23694121 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL17331216 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL2380644 | 0.93 | KDM4E (0.40) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| Dimethyl Succinate SCHEMBL29206226 | 0.85 | TSHR (0.39) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL8464466 | 0.85 | KDM4E (0.42) | KDM4EALDH1A1TDP1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3966226-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| WO-2020225095-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-12 | — | — | WO | disclosed |
| EP-3622968-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | The General Hospital Corporation (US) | 2020-03-18 | — | — | EP | disclosed |
| US-8900549-B2 | Compositions and methods for delivering a substance to a biological target | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-8859549-B2 | Potassium channel modulators | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130302246-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | THE GENERAL HOSPITAL CORPORATION | 2013-11-14 | — | — | US | disclosed |
| US-20130272959-A1 | AGENTS FOR CLEARING BIOMOLECULES FROM CIRCULATION | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2013-10-17 | — | — | US | disclosed |
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120039803-A1 | PRETARGETING KIT, METHOD AND AGENTS USED THEREIN | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2012-02-16 | — | — | US | disclosed |
| US-20120034161-A1 | PRETARGETING KIT, METHOD AND AGENTS USED THEREIN | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2012-02-09 | — | — | US | disclosed |
| US-20110268654-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | THE GENERAL HOSPITAL CORPORATION (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | SLC6A12 4014/4885SLC6A11 3639/4885SLC6A13 3390/4885 |
| US-20130272959-A1 | AGENTS FOR CLEARING BIOMOLECULES FROM CIRCULATION | FCGR3B, C3AR1, CX3CR1 | SLC6A12 4088/4885SLC6A11 4158/4885SLC6A13 4138/4885 |
| US-20120034161-A1 | PRETARGETING KIT, METHOD AND AGENTS USED THEREIN | KIT, PAICS, PROKR2 | SLC6A12 1606/4885SLC6A11 4371/4885SLC6A13 3897/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | SLC6A12 4014/4885SLC6A11 3639/4885SLC6A13 3390/4885 |
| US-20110268654-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | FCER2, EPCAM, EPHA2 | SLC6A12 4465/4885SLC6A11 2865/4885SLC6A13 2748/4885 |
| US-20120039803-A1 | PRETARGETING KIT, METHOD AND AGENTS USED THEREIN | KIT, PROKR2, RET | SLC6A12 834/4885SLC6A11 3983/4885SLC6A13 3384/4885 |
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNJ2 | SLC6A12 2466/4885SLC6A11 262/4885SLC6A13 396/4885 |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNQ3 | SLC6A12 2038/4885SLC6A11 244/4885SLC6A13 344/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | SLC6A12 4014/4885SLC6A11 3639/4885SLC6A13 3390/4885 |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | SLC6A12 4014/4885SLC6A11 3639/4885SLC6A13 3390/4885 |
| US-20130302246-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | FCER2, EPCAM, EPHA2 | SLC6A12 4465/4885SLC6A11 2865/4885SLC6A13 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.